New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 2, 2014
05:53 EDTMNKDPanel raised questions about Afrezza's commercial outlook, says Piper Jaffray
Piper Jaffray believes the issues discussed as yesterday's FDA panel meeting raise questions regarding the commercial outlook for Afrezza. Piper believes FDA approval of the drug "seems inevitable" with yesterday's positive vote, but it sees challenges ahead and raised its price target for MannKind shares to only $2.00 from $1.50. It keeps an Underweight rating on the stock.
News For MNKD From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 29, 2014
19:32 EDTMNKDMannKind confirms receipt of $150M licensing upfront payment
Subscribe for More Information
September 24, 2014
17:01 EDTMNKDMannKind announces closing of global licensing agreement with Sanofi
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use